Ranbaxy confident in quality of products in Australia

Generic drug manufacturer, Ranbaxy, is confident the products it supplies to the Australian market are of a high quality, following the US Food and Drug Administration’s (FDA) decision to block imports of products from three of the company’s plants in India.

The move to block the importation of products from the Toansa plant, the source of more than two thirds of the active pharmaceutical ingredient used to manufacture Ranbaxy's US products, came after concerns were raised about lapses in quality